Immedica announces sale of priority review voucher for USD 200 million

STOCKHOLM, Sweden, May 18, 2026 -  Immedica Pharma announced today that it has completed the sale of its priority review voucher (PRV) for a total cash consideration of USD 200 million.

Immedica was awarded the PRV in February 2026, following the approval by the U.S. Food and Drug Administration of Loargys® (pegzilarginase-nbln) for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction.

Jefferies LLC acted as exclusive financial advisor and Latham & Watkins LLP acted as legal counsel to Immedica on this transaction.

About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within RARE metabolic, RARE hematology & oncology, RARE neurology, RARE endocrinology and specialty care. Immedica was founded in 2018 and employs today around 180 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo.

For more information visit www.immedica.com.

Immedica contact:
Linda Holmström
VP, Head of HR & Communication
[email protected]